ArticleFrontiers in oncology2025
Rare metastasis of the urinary bladder from esophageal squamous cell carcinoma: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Squamous cell carcinoma (SCC) of the urinary bladder is rare, comprising less than 5% of all bladder cancers. There have been no previous reports of bladder SCC occurring as a metachronous metastatic tumor following curative resection for esophageal squamous carcinoma. This case report aims to address the challenges in treatment strategy posed by such occurrences by presenting a case of esophageal SCC with subsequent bladder metastasis. Case description: The patient is a 57-year-old Asian male with a 40-year history of heavy smoking. In July 2020, he was diagnosed with esophageal SCC, staged as cT2N1M0, and underwent radical surgery followed by adjuvant radiotherapy, chemotherapy, and immunotherapy. Post-surgery, he remained asymptomatic with regular check-ups showing no recurrence until November 2021, when he presented with hematuria. An MRU indicated a solid lesion in the bladder, and biopsy confirmed poorly differentiated SCC. A partial cystectomy was performed, followed by chemotherapy. Despite stable initial follow-ups, elevated CEA and SCC-Ag levels later suggested recurrence, confirmed by PET-CT and pathological examination showing lymph node metastases around the esophagus and in the neck. Subsequently, chemotherapy combined with immunotherapy was recommended. Conclusion: For solitary metachronous metastatic SCC of the bladder following esophageal SCC, surgical resection combined with postoperative adjuvant chemotherapy can be a viable treatment option. Partial cystectomy may be feasible for patients without lymphatic spread and who wish to preserve bladder function. Tumor markers CEA and SCC-Ag have proven effective in monitoring postoperative metastasis and can serve as reliable indicators for tumor follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.